Evidence map›Paper›PMID 42502235›Full record

ArticleClinical pharmacology and therapeutics2026

Beyond Hy's Law: Importance of Markedly Elevated Aminotransferases without Hyperbilirubinemia.

Naga Chalasani, Ismael Alvarez-Alvarez, Paul H Hayashi, Raj Vuppalanchi, Marwan Ghabril, Ronald Kamusiime, Huiman Barnhart, Hao Niu, M Isabel Lucena, Raul J Andrade and 1 more

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Naga ChalasaniDivision of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0003-4082-3178
Ismael Alvarez-AlvarezServicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA) - Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.ORCID https://orcid.org/0000-0001-6271-0604
Paul H HayashiFood and Drug Administration, Silver Spring, Maryland, USA.ORCID https://orcid.org/0000-0002-5371-1020
Raj VuppalanchiDivision of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0003-0637-1577
Marwan GhabrilDivision of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Ronald KamusiimeDuke University, Durham, North Carolina, USA.ORCID https://orcid.org/0009-0009-5848-0493
Huiman BarnhartDuke University, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0003-0988-3439
Hao NiuServicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA) - Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.ORCID https://orcid.org/0000-0002-3030-3972
M Isabel LucenaServicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA) - Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.ORCID https://orcid.org/0000-0001-9586-4896
Raul J AndradeServicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA) - Plataforma BIONAND, Universidad de Málaga, Málaga, Spain.ORCID https://orcid.org/0000-0002-1565-0757
Drug Induced Liver Injury Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated aminotransferases with concomitant jaundice in drug-induced liver injury (DILI) are associated with adverse outcomes, but the prognostic significance of very high aminotransferases without jaundice is unclear. We examined selected outcomes of patients with DILI and markedly elevated aminotransferases but normal or near-normal total bilirubin (TBL). We analyzed the data from the prospective Drug-Induced Liver Injury Network (DILIN) and the Spanish DILI registries. Patients were categorized based on peak alanine or aspartate aminotransferase (ALT/AST) levels-very high (500-1,000 U/L) or towering (>1,000 U/L)-and concomitant normal (≤1.0 mg/dL) or near-normal (1.1-2.5 mg/dL) TBL levels. Primary outcome was subsequent development of nR-based Hy's Law (nR ≥5 with TBL >2.5 mg/dL). A total of 964 patients were analyzed (692 DILIN; 272 Spanish DILI). In both cohorts, very high aminotransferases with normal TBL were rarely followed by nR-based Hy's Law. In DILIN, only 1.3% of patients with very high ALT and normal TBL developed nR-based Hy's Law, whereas risk increased markedly with minimally elevated TBL (odds ratio (OR) 7.8). Towering aminotransferases conferred increased risk regardless of TBL, with the highest risk observed when accompanied by minimally elevated TBL (OR 23.6). Similar inflection points were observed in the Spanish DILI Registry, in patients with very high aminotransferases and minimally elevated TBL or towering aminotransferases with or without elevated TBL. In conclusion, patients with DILI and very high aminotransferases may tolerate liver injury well when bilirubin is normal, but even minimal bilirubin elevation or towering aminotransferases signal increased risk for poor outcomes.

Indexed as

Alanine TransaminaseAspartate AminotransferasesChemical and Drug Induced Liver InjuryHyperbilirubinemiaAgedBilirubinBiomarkersFemaleHumansJaundiceMaleMiddle AgedPrognosisProspective StudiesRegistriesRisk FactorsAlanine TransaminaseAspartate AminotransferasesBilirubinBiomarkers

Identifiers

PMID42502235
PMCPMC13401666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.